Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT studyKevin C. Flanagan, Eric J. Duncavage, William H. Westra et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 9
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinomaKevin C. Flanagan, Eric J. Duncavage, Jon Earls et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 8
Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT StudyKevin C. Flanagan, Eric J. Duncavage, Jon Earls et al.|medRxiv|2024Cited by 1